Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Kidney Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Bevacizumab 5Capecitabine 3toripalimab 2olaparib 2durvalumab 2darolutamide 2atezolizumab 2apatinib 2anlotinib 2Standard of Care 2Radiotherapy 2Radiosurgery 2Oxaliplatin 2Leucovorin 2Laparoscopy 2Immunotherapy 2Fluorouracil 2Drug Therapy 2130-nm albumin-bound paclitaxel 2trametinib 1spartalizumab 1pyrotinib 1pomalidomide 1palbociclib 1nilotinib 1ledipasvir, sofosbuvir drug combination 1ledipasvir 1irinotecan sucrosofate 1hetrombopag 1glasdegib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Blood Cell Count × 90 days × Clear all
NCT07485114 2026-03-20

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Tel-Aviv Sourasky Medical Center

Recruiting
300 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡